2026-09-19T12:37:15Zhttps://dspace.mit.edu/server/oai/request

oai:dspace.mit.edu:1721.1/527902022-01-13T07:54:33Zcom_1721.1_7582com_1721.1_7581col_1721.1_131022

Michael J. Cima. Ho Duc, Hong Linh, 1978- Massachusetts Institute of Technology. Dept. of Materials Science and Engineering. Massachusetts Institute of Technology. Department of Materials Science and Engineering 2010-03-24T20:37:51Z 2010-03-24T20:37:51Z 2009 2009 http://hdl.handle.net/1721.1/52790 537302298 Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Materials Science and Engineering, 2009. This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections. Cataloged from student submitted PDF version of thesis. Includes bibliographical references. An implantable rapid drug delivery device based on micro-electro-mechanical systems (MEMS) technology was designed, fabricated and validated for the in vivo rapid delivery of vasopressin in a rabbit model. In vitro characterization of device performance found the device capable of reliably and reproducibly delivering 85% of its loaded drug solution. A comparison of intraperitoneal and subcutaneous injections of vasopressin in rabbits was performed to determine the implantation location for the device. Both routes of delivery were found to be viable implantation locations, and the less invasive subcutaneous site was chosen. Vasopressin was released from the subcutaneously implanted device in anesthetized rabbits and found to exert a measurable effect on blood pressure. The bioavailability of vasopressin delivered from the device was found to be 6.2% after one hour. Proof-of-concept experiments were also conducted to address long-term stability of drugs in the implanted device and wireless activation of the device. These experiments defined areas of future research for improvement of the device. by Hong Linh Ho Duc. Ph.D. 86 p. eng Massachusetts Institute of Technology M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 Materials Science and Engineering. Emergency delivery of Vasopressin from an implantable MEMS rapid drug delivery device Thesis application/pdf Publication unknown unknown <Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="1e450227-aa5c-4923-b225-81111f3f90dc"> <Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type> <Language>eng</Language> <Title>Emergency delivery of Vasopressin from an implantable MEMS rapid drug delivery device</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2009</PublicationDate> <Authors> <Author> <DisplayName>Ho Duc, Hong Linh, 1978-</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <DisplayName>Massachusetts Institute of Technology</DisplayName> <OrgUnit /> </Publisher> </Publishers> <License>http://dspace.mit.edu/handle/1721.1/7582</License> <Keyword>Materials Science and Engineering.</Keyword> <Abstract>An implantable rapid drug delivery device based on micro-electro-mechanical systems (MEMS) technology was designed, fabricated and validated for the in vivo rapid delivery of vasopressin in a rabbit model. In vitro characterization of device performance found the device capable of reliably and reproducibly delivering 85% of its loaded drug solution. A comparison of intraperitoneal and subcutaneous injections of vasopressin in rabbits was performed to determine the implantation location for the device. Both routes of delivery were found to be viable implantation locations, and the less invasive subcutaneous site was chosen. Vasopressin was released from the subcutaneously implanted device in anesthetized rabbits and found to exert a measurable effect on blood pressure. The bioavailability of vasopressin delivered from the device was found to be 6.2% after one hour. Proof-of-concept experiments were also conducted to address long-term stability of drugs in the implanted device and wireless activation of the device. These experiments defined areas of future research for improvement of the device.</Abstract> <Access xmlns="http://purl.org/coar/access_right" > </Access> </Publication>